Home›Suvorexant

Suvorexant

Also known as: Belsomra

Orexin Receptor AntagonistOrexin Receptor AntagonistsP-Glycoprotein Inhibitors

Route: Oral

Check Suvorexant Interactions →

29 interactions on record

Suvorexant has 29 known drug interactions based on U.S. FDA drug labeling data. Of these, 13 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Boceprevir, Clarithromycin, Conivaptan. Patients taking Suvorexant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 29
Contraindicated: 13
Major: 3
Moderate: 13

Contraindicated (13)

Suvorexant + Boceprevir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Clarithromycin— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Conivaptan— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Indinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Itraconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Ketoconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Nefazodone— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Nelfinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Posaconazole— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Ritonavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Saquinavir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Telaprevir— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.
Suvorexant + Telithromycin— Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Major (3)

Suvorexant + Carbamazepine— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.
Suvorexant + Phenytoin— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.
Suvorexant + Rifampin— Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Moderate (13)

Suvorexant + Alcohol— Additive psychomotor impairment demonstrated when co-administered with suvorexant.
Suvorexant + Amprenavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Aprepitant— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Atazanavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Ciprofloxacin— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Digoxin— Suvorexant slightly increases digoxin levels by inhibiting intestinal P-gp; monitor digoxin concentrations.
Suvorexant + Diltiazem— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Erythromycin— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Fluconazole— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Fosamprenavir— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Grapefruit Juice— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Suvorexant + Imatinib— The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, …
Suvorexant + Verapamil— Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Boceprevir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Clarithromycin⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Conivaptan⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Indinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Itraconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Ketoconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Nefazodone⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Nelfinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Posaconazole⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Ritonavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Saquinavir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Telaprevir⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Telithromycin⛔Contraindicated

Strong CYP3A inhibitor; concomitant use not recommended due to increased suvorexant exposure.

Suvorexant + Carbamazepine⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Phenytoin⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Rifampin⚠️Major

Strong CYP3A inducer; substantially decreases suvorexant exposure and may reduce efficacy.

Suvorexant + Alcohol🟡Moderate

Additive psychomotor impairment demonstrated when co-administered with suvorexant.

Suvorexant + Amprenavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Aprepitant🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Atazanavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Ciprofloxacin🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Digoxin🟡Moderate

Suvorexant slightly increases digoxin levels by inhibiting intestinal P-gp; monitor digoxin concentrations.

Suvorexant + Diltiazem🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Erythromycin🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Fluconazole🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Fosamprenavir🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Grapefruit Juice🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Suvorexant + Imatinib🟡Moderate

The recommended dose of BELSOMRA is 5 mg in subjects receiving moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil).

Suvorexant + Verapamil🟡Moderate

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations